Article
Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
Clinical lung cancer - 1 Jul 2022
Behel Vichitra, Chougule Anuradha, Noronha Vanita, Patil Vijay Maruti, Menon Nandini, Singh Ajaykumar, Chopade Sunil, Kumar Rajiv, Shah Srushti, More Sucheta, Banavali Shripad Dinanath, Chandrani Pratik, Prabhash Kumar
Abstract excerpt
INTRODUCTION: Plasma cfDNA-based mutation analysis has shown disease-monitoring potential in various cancers. We assessed the potential of cfDNA-based EGFR mutation testing as a monitoring tool in patients with NSCLC. PATIENTS AND METHODS: Patients with NSCLC harboring EGFR mutations receiving first-line treatment as per institutional protocol were enrolled. EGFR mutation status was determined using plasma...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.